Towards transparency: adoption of WHO best practices in clinical trial registration and reporting among top medical research funders in the USA
- PMID: 37932014
- DOI: 10.1136/bmjebm-2023-112395
Towards transparency: adoption of WHO best practices in clinical trial registration and reporting among top medical research funders in the USA
Abstract
Objective: To assess to what extent the clinical trial policies of the largest public and philanthropic funders of clinical research in the United States meet WHO best practices in trial registration and reporting.
Methods: Public and philanthropic funders of clinical trials in the USA with >US$50 million annual spend were selected. The funders were assessed using an 11-item scoring tool based on WHO Joint Statement benchmarks. These 11 items fell into 4 categories, namely: trial registration, academic publication, monitoring and sanctions. An additional item captured whether and how funders referred to Consolidated Standards of Reporting Trials (CONSORT) within their trial policies. Each funder was independently assessed by two or three researchers. Funders were contacted to flag possible errors and omissions. Ambiguous or difficult-to-score items were settled by an independent adjudicator.
Results: Fourteen funders were assessed. Our cross-sectional study found that, on average, funders have only implemented 4.1/11 (37%) of WHO best practices in clinical trial transparency. The most frequently adopted requirement was open access publishing (14/14 funders). The least frequently adopted were (1) requiring trial ID to appear in all publications (2/14 funders, 14%) and (2) making compliance reports public (2/14 funders, 14%). Public funders, on average, adopted more policy elements (5.2/11 items, 47%) than philanthropic funders (2.8/11 items, 25%). Only one funder's policy documents mentioned the CONSORT statement.
Conclusions: There is a significant variation between the number of best practice policy items adopted by medical research funders in the USA. Many funders fell significantly short of WHO Joint Statement benchmarks. Each funder could benefit from policy revision and strengthening.
Keywords: drug development; health care quality, access, and evaluation; policy.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: SK and ARS both belong to the Universities Allied for Essential Medicines (UAEM) and the People’s Health Movement on a voluntary basis. TB is the founder of TranspariMED.
Similar articles
-
Adoption of World Health Organization Best Practices in Clinical Trial Transparency Among European Medical Research Funder Policies.JAMA Netw Open. 2022 Aug 1;5(8):e2222378. doi: 10.1001/jamanetworkopen.2022.22378. JAMA Netw Open. 2022. PMID: 35913742 Free PMC article.
-
Noncommercial US Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.JAMA Netw Open. 2019 Jan 4;2(1):e187498. doi: 10.1001/jamanetworkopen.2018.7498. JAMA Netw Open. 2019. PMID: 30681715 Free PMC article.
-
Are European clinical trial funders policies on clinical trial registration and reporting improving? A cross-sectional study.J Clin Transl Sci. 2023 Jul 14;7(1):e166. doi: 10.1017/cts.2023.590. eCollection 2023. J Clin Transl Sci. 2023. PMID: 37588679 Free PMC article.
-
Do emergency medicine journals promote trial registration and adherence to reporting guidelines? A survey of "Instructions for Authors".Scand J Trauma Resusc Emerg Med. 2016 Nov 24;24(1):137. doi: 10.1186/s13049-016-0331-3. Scand J Trauma Resusc Emerg Med. 2016. PMID: 27881175 Free PMC article. Review.
-
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.BMJ Open. 2015 Nov 12;5(11):e009758. doi: 10.1136/bmjopen-2015-009758. BMJ Open. 2015. PMID: 26563214 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources